Spinal Muscular Atrophy

FDA Approves Novartis’ Itvisma: Expanding Gene Therapy to Older Spinal Muscular Atrophy Patients

1 week ago talkbio0Tagged Adult, Approved, gene therapy, intrathecal formulation, Itvisma, Novartis, older children, Spinal Muscular Atrophy, United States Food and Drug Administration, Zolgensma

Novartis; FDA approval; Itvisma; Zolgensma; Spinal Muscular Atrophy (SMA); Gene Therapy; Older Children; Adults; Intrathecal Formulation

Biogen Plans Resubmission After FDA Declines High-Dose Spinraza for SMA, Requests More Production Information

2 months ago talkbio0Tagged Biogen, Candidiasis, Chronic Mucocutaneous, Complete, controls, High dose, Manufacturing, New Drug Application, nusinersen, regulatory, Response Letter, resubmission, Science of Chemistry, Spinal Muscular Atrophy, Spinraza, United States Food and Drug Administration

Biogen; Spinraza; nusinersen; high dose; FDA; Complete Response Letter; spinal muscular atrophy; SMA; supplemental New Drug Application; Chemistry Manufacturing and Controls; CMC; regulatory; resubmission

FDA Rejects Scholar Rock’s SMA Drug Due to Catalent Indiana Manufacturing Issues

2 months ago talkbio0Tagged apitegromab, Catalent Indiana, Complete, Drug Approval, manufacturing issues, Response Letter, Scholar Rock, SMA, Spinal Muscular Atrophy, United States Food and Drug Administration

FDA; Scholar Rock; Apitegromab; SMA; Spinal Muscular Atrophy; Catalent Indiana; Complete Response Letter; Manufacturing issues; Drug approval

Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies

5 months ago talkbio0Tagged Antistreptolysin O, Biogen, Clinical Trials, motor milestones, Nerve Degeneration, Novartis, Pediatric brand name, Phase III, salanersen, Spinal Muscular Atrophy, Spinraza, Zolgensma

Biogen; SMA; Spinraza; salanersen; Phase III; clinical trials; neurodegeneration; motor milestones; pediatric; Novartis Zolgensma; ASO therapy

Scholar Rock’s SMA drug helps Zepbound patients retain muscle in phase 2 trial

6 months ago talkbio0Tagged apitegromab, GDF8 protein, human, Inhibitor, Lean Mass, muscle preservation, Obesity, Phase 2 trial, Scholar Rock, Spinal Muscular Atrophy, Weight Loss, Zepbound

Scholar Rock; apitegromab; SMA drug; Zepbound; tirzepatide; muscle preservation; obesity; weight loss; phase 2 trial; lean mass; myostatin inhibitor

Novartis Prepares to File Intrathecal Zolgensma for Older SMA Patients by Mid-2025

9 months ago talkbio0Tagged gene therapy, intrathecal delivery, older, Spinal Muscular Atrophy, Zolgensma

Zolgensma, intrathecal delivery, spinal muscular atrophy, gene therapy, older patients

FDA Approves Evrysdi Tablets: A Breakthrough in Convenient SMA Treatment

10 months ago talkbio0Tagged Approved, Drug Formulation Process, Evrysdi, genentech, Oral treatment, Risdiplam, Roche (company), Spinal Muscular Atrophy, Tablet Dosage Form, United States Food and Drug Administration

Evrysdi, risdiplam, spinal muscular atrophy (SMA), FDA approval, tablet formulation, oral treatment, Genentech, Roche

Novartis Achieves Pivotal Trial Success for Intrathecal Zolgensma in Older SMA Patients After FDA Delay

11 months ago talkbio0Tagged Approved, intrathecal formulation, Novartis, older, Phase 3 trial, Spinal Muscular Atrophy, United States Food and Drug Administration, Zolgensma

Novartis, Zolgensma, Intrathecal formulation, Spinal muscular atrophy (SMA), FDA approval, Pivotal phase 3 trial, Older SMA patients

Biohaven’s Taldefgrobep Alfa Shifts Focus to Obesity After Missing Primary Endpoint in Spinal Muscular Atrophy Phase 3 Trial

1 year ago talkbio0Tagged Alfa, Body Composition, Bone and Bones, density, GDF8 protein, human, Inhibitor, lean, Obesity, Phase 3 trial, Spinal Muscular Atrophy

Biohaven, taldefgrobep alfa, spinal muscular atrophy (SMA), obesity, myostatin inhibitor, phase 3 trial, body composition, lean muscle mass, bone density.

Biohaven’s Taldefgrobep Alfa Misses Primary Endpoint in Phase 3 SMA Trial, Eyes FDA Discussions and Obesity Indication

1 year ago talkbio0Tagged Discussion (procedure), Indication of (contextual qualifier), Obesity, Phase 3 trial, Spinal Muscular Atrophy, Talditercept alfa, United States Food and Drug Administration

Biohaven, Taldefgrobep Alfa, Spinal Muscular Atrophy (SMA), Phase 3 Trial, FDA Discussions, Obesity Indication